Last CNY50.61 CNY
Change Today -1.46 / -2.80%
Volume 1.7M
000513 On Other Exchanges
Symbol
Exchange
Shenzhen
Hong Kong
Frankfurt
As of 10:30 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

livzon pharmaceutical grou-a (000513) Snapshot

Open
CNY51.71
Previous Close
CNY52.07
Day High
CNY51.90
Day Low
CNY50.35
52 Week High
10/10/14 - CNY58.69
52 Week Low
12/27/13 - CNY37.60
Market Cap
13.7B
Average Volume 10 Days
2.1M
EPS TTM
CNY1.80
Shares Outstanding
183.8M
EX-Date
07/25/14
P/E TM
28.2x
Dividend
CNY0.50
Dividend Yield
0.99%
Current Stock Chart for LIVZON PHARMACEUTICAL GROU-A (000513)

Related News

No related news articles were found.

livzon pharmaceutical grou-a (000513) Related Businessweek News

No Related Businessweek News Found

livzon pharmaceutical grou-a (000513) Details

Livzon Pharmaceutical Group Inc. is engaged in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China and internationally. Its products primarily include Chinese and Western drug preparation products, such as Shengqi Fuzheng Injection, a series of Bismuth Potassium Citrate Granules products, anti-viral granules, Urofollitropin for injection, Menotropins for injection, Ilaprazole, Leuprorelin Acetate Microspheres for injection, Cefodizime Sodium for injection, Voriconazole for injection, and mouse nerve growth factor for injection. The company’s products also comprise bulk medicines and intermediates, including Mevastatin, Colistin, Phenylalanine, Ceftriaxone Sodium, Cefuroxime Sodium, and Cefodizime Sodium; and diagnostic reagent products, such as ELISA HIV testing reagent, MYCOII testing reagent, and TPPA testing reagent. In addition, the company provides chemical drugs, biochemical drugs, microbiological preparations, and antibiotics; polypeptide bulk medicines; diagnostic reagents and equipment; human chorionic Gonadotrophin for injection; Omeprazole Sodium for injection; Ranitidine Bismuth Citrate tablets; Valaciclovir Hydrochloride tablets; Fluvoxamine Maleate tablet; Perospirone Hydrochloride tablets; and Prostant used for the treatment of clearing away heat evil and promoting diuresis. Further, it manufactures fermented antibiotics, sterile cephalosporins, and hypolipidemic statin. Livzon Pharmaceutical Group Inc. was founded in 1985 and is based in Zhuhai, China.

Founded in 1985

livzon pharmaceutical grou-a (000513) Top Compensated Officers

President, Executive Director, Member of Nomi...
Total Annual Compensation: CNY686.4K
Chief Supervisor
Total Annual Compensation: CNY248.6K
Chief Supervisor
Total Annual Compensation: --
Supervisor
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

livzon pharmaceutical grou-a (000513) Key Developments

Livzon Pharmaceutical Group Inc. Presents at Citi China Investor Conference 2014, Nov-05-2014

Livzon Pharmaceutical Group Inc. Presents at Citi China Investor Conference 2014, Nov-05-2014 . Venue: Grand Hyatt, Macau, China. Speakers: Liang Yang, Company Secretary.

Livzon Pharmaceutical Group Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Livzon Pharmaceutical Group Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the period, the company has posted total operating income of RMB 1,491,710,662.63 against RMB 1,071,097,691.06 a year ago. Operating profit was RMB 135,692,887.61 against RMB 139,897,359.19 a year ago. Profit before income tax was RMB 173,418,267.49 against RMB 155,210,563.53 a year ago. Net profit attributable to the shareholders of the parent company was RMB 132,375,173.14 or RMB 0.45 basic and diluted per share against RMB 119,424,573.63 or RMB 0.40 basic and diluted per share a year ago. For the nine months, the company has posted total operating income of RMB 4,120,184,989.01 against RMB 3,233,359,513.46 a year ago. Operating profit was RMB 480,562,643.18 against RMB 448,420,598.53 a year ago. Profit before income tax was RMB 540,635,467.25 against RMB 477,310,174.68 a year ago. Net profit attributable to the shareholders of the parent company was RMB 423,309,229.92 or RMB 1.43 basic and diluted per share against RMB 378,734,988.27 or RMB 1.28 basic and diluted per share a year ago.

Livzon Pharmaceutical Group Inc. to Report Q3, 2014 Results on Oct 28, 2014

Livzon Pharmaceutical Group Inc. announced that they will report Q3, 2014 results on Oct 28, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
000513:CH CNY50.61 CNY -1.46

000513 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 000513.
View Industry Companies
 

Industry Analysis

000513

Industry Average

Valuation 000513 Industry Range
Price/Earnings 28.7x
Price/Sales 2.8x
Price/Book 4.2x
Price/Cash Flow 17.8x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIVZON PHARMACEUTICAL GROU-A, please visit www.livzon.com.cn/english/. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.